| December 4, 2005
Lawyers debate the Vioxx studies in light of the recent trials. It’s Evan vs Ted in the comments. (via a reader tip by CJD)
< Previous post Previous Post
Next post > Next Post
Comments are moderated before they are published. Please read the comment policy.
Hm, the last guy comes up with numbers of heart attack for one day of taking vioxx, then he changes them to fatal heart attacks… must be a lawyer.
Evan, actually it appears that the battle is between Ted and this guy:
He’s got two posts on the subject of Vioxx here, and appears to be a statistician, not a lawyer. I’m afraid your renowned investigatory skills failed you again Anonymous:
A couple of highlights from the two posts:
“In other words, Calfee and the “tort reformers” think the views of a pharmacology professor at a top university, the FDA advisory panel, and the editors of major medical journals are “junk science.” With the whole medical establishment in the wrong, it’s hard to imagine where we can find any “sound science.” At the American Tort Reform Association and the AEI?”
“From the point of view of economic efficiency, I think Merck is going to end up paying too much, even leaving aside any bogus lawsuits that are filed. Merck ought to be liable for the excess heart attacks and other diseases they caused, not the illness that would have occurred if Vioxx had never been invented. But even though only about a third of the heart attacks suffered by Vioxx users were actually caused by Vioxx, there’s no way to tell which are which. So Merck will probably end up paying for all of them.
I don’t see any way around this, except for dividing the court awards by three, which might not be such a bad idea.”
The best of KevinMD.com.
Only on Facebook.
"A comprehensive and extremely useful roadmap for doctors."
-Eric Topol, MD, author of The Creative Destruction of Medicine
site by Out:think Group
Welcome to KevinMD.com, social media's leading physician voice.
Receive regular updates delivered free to your inbox.
KevinMD.com is also on Facebook, Twitter and LinkedIn.